United Therapeutics (UTHR) Reaches New Lifetime High Today

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified United Therapeutics ( UTHR) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified United Therapeutics as such a stock due to the following factors:

  • UTHR has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $144.9 million.
  • UTHR has traded 6,518 shares today.
  • UTHR is trading at a new lifetime high.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in UTHR with the Ticky from Trade-Ideas. See the FREE profile for UTHR NOW at Trade-Ideas

More details on UTHR:

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. UTHR has a PE ratio of 24.4. Currently there are 4 analysts that rate United Therapeutics a buy, no analysts rate it a sell, and 5 rate it a hold.

The average volume for United Therapeutics has been 836,600 shares per day over the past 30 days. United has a market cap of $5.9 billion and is part of the health care sector and drugs industry. The stock has a beta of 1.57 and a short float of 16.5% with 4.30 days to cover. Shares are up 11.9% year-to-date as of the close of trading on Monday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Biotech Movers: Buzz on Potential Suitors Sends United Therapeutics Stock Soaring

United Therapeutics, DOJ in Possible Settlement Over Drug Contributions

Alexion Spikes on Q2 Earnings Blowout Providing Positive Signs for Rest of Sector -Biotech Movers

Biotech Movers: Novocure, United Therapeutics, Kite Pharma

United Therapeutics Stock Slumping on Credit Suisse Rating